Wed, Aug 14, 7:57 PM (153 days ago)
On August 12, 2024, 60 Degrees Pharmaceuticals, Inc. announced a significant development regarding its drug ARAKODA® (tafenoquine). The company granted the University of Kentucky a right of reference for its new drug application, enabling the U.S. FDA to review essential clinical efficacy and safety data, along with manufacturing information. This move supports the FDA's evaluation of the University’s investigational SJ733 Phase IIb program. The announcement, made via a press release incorporated into the Form 8-K, indicates the company's proactive stance in collaborating with academic institutions to advance drug development. As an emerging growth company, 60 Degrees Pharmaceuticals continues to navigate the regulatory landscape, potentially impacting its financial position and stock value positively as it progresses through the FDA review process.